Home › Compound Library › Sertraline (Zoloft)

Sertraline (Zoloft)

SSRIprescriptionoral · inferred

Selective serotonin reuptake inhibitor for depression and anxiety. Metabolite desmethylsertraline is weakly active with a much longer half-life (62-104h).

Projected serum levels — 50 mg, once daily

Sertraline (Zoloft)
Sertraline (Zoloft) modeled serum levels, 50 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 4 days. 0 0.63 1.3 1.9 2.5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 4
Sertraline (Zoloft) modeled serum levels with a loading dose of 109 mg, then 50 mg once daily The first dose is larger so levels approach steady state faster. 0 0.63 1.3 1.9 2.5 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 50 mg once daily (oral).

Loading schedule: 109 mg on day 1, then 50 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~4 days: peak ≈ 2.1 mg, trough ≈ 1.3 mg body load. Population-based estimate over 15 days for a 50 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
SSRI
Route modeled
Oral
Model confidence
inferred
Half-life
26 h
Common dose
50 mg
Suggested maximum
200 mg/day
Reference dose range
25–200 mg (single dose)
Suggested cadence
once daily
Validated against
100 mg oral — Cmax 0.025 mg/L at 6 h

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Sertraline (Zoloft) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Sertraline (Zoloft) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Sertraline (Zoloft) Serotonin risk

    25I-NBOMe and Sertraline (Zoloft) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Sertraline (Zoloft) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Sertraline (Zoloft) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Sertraline (Zoloft) Serotonin risk

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Sertraline (Zoloft) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Sertraline (Zoloft) Serotonin risk

    4-AcO-DMT (Psilacetin) and Sertraline (Zoloft) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-MMC (Mephedrone) + Sertraline (Zoloft) CYP inhibition

    Sertraline (Zoloft) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

Serum checks 440 modeled interaction pairings for sertraline (zoloft) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Sertraline treatment of major depression in patients with acute MI or unstable angina (SADHART) Glassman AH et al. · JAMA, 2002 DOI

    Landmark trial demonstrating sertraline is safe and effective for treating depression in patients with acute coronary syndromes, with no adverse cardiac effects.

  2. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis Cipriani A et al. · Lancet, 2018 DOI

    Major network meta-analysis of 522 trials ranked sertraline among the most effective and best-tolerated antidepressants, making it a strong first-line choice.

2 published studies referenced in the app, each with a plain-language summary.